2026-03-27 (五) 18:30 ~ 20:30

線上會議：

實體： JR東日本飯店 3F(請於下方點擊報名)

Chronic rhinosinusitis with nasal polyps (CRSwNP) is commonly driven by type 2 eosinophilic inflammation. Anti-IL-5 biologics have emerged as an important treatment option for patients with severe or refractory disease. This session will review the role of IL-5 in CRSwNP and share expert clinical experiences with anti-IL-5 therapy, focusing on patient selection, treatment outcomes, and practical considerations in real-world practice.